Table I.
Baseline Patient Characteristics1
| Characteristics | Intention to Treat Analysis Population (n = 15) | As Treated Analysis Population (n = 10) |
|---|---|---|
| Sex | ||
| Male | 2 (13.33) | 1 (10) |
| Female | 13 (86.67) | 9 (90) |
| Age, y | ||
| Mean (median) [25th percentile, 75th percentile] | 42 (45) [30, 50] | 42.9 (46.5) [30, 53] |
| Race | ||
| White | 12 (80) | 9 (90) |
| Black | 3 (20) | 1 (10) |
| Baseline Assessments - Mean (median) [25th percentile, 75th percentile] | ||
| Physician’s Global Assessment (PGA) - | ||
| 10 cm Visual Analogue Scale Score | 4.17 (4.35) [3.1, 4.8] | 4.26 (4.55) [3.5, 4.8] |
| Number of Lesions | 14.07 (14) [8, 19] | 14.9 (14) [9, 19] |
| Patient Pain - | ||
| 10 cm Visual Analogue Scale Score | 6.19 (6.4) [4.5, 7.4] | 6.6 (7.25) [5.5, 7.9] |
| Dermatology Life Quality Index (DLQI)2 | 20.4 (19) [14, 29] | 21.5 (20.5) [16, 29] |
| Duration of Disease, y | ||
| Mean (median) [range] | 15.46 (12) [1–36] | 13 (11.5) [1–35] |
| Prior Systemic and Intralesional Therapies | 14 (93.3) | 9 (90) |
| Oral Antibiotics | 9 (60) | 6 (60) |
| Accutane | 8 (53.3) | 4 (40) |
| Surgery | 3 (20) | 3 (30) |
| Intralesional corticosteroids | 2 (13.3) | 0 |
| Oral contraceptives | 1 (6.7) | 1 (10) |
| Oral corticosteroids | 1 (6.7) | 0 |
| Injected antibiotics | 1 (6.7) | 1 (10) |
| Ketoconazole | 1 (6.7) | 1 (10) |
| Nicomide | 1 (6.7) | 1 (10) |
| Spironolactone | 1 (6.7) | 1 (10) |
| Cimetidine | ||
| Body Mass Index (BMI), kg/m2 | ||
| Mean (median) [range] | 35.1 (35.1) [17.9–47.5] | 37.03 (37.4) [25.2–47.5] |
1
Values expressed as number(percentage) unless otherwise indicated.
2
Meaning of DLQI Scores: 0–1 = no effect at all on patient’s life, 2–5 = small effect on patient’s life, 6–10 = moderate effect on patient’s life, 11–20 = very large effect on patient’s life, 21–30 = extremely large effect on patient’s life